Mirador Therapeutics, Inc., a San Diego, CA-based company advancing multiple therapeutic programs, raised $400m in financing.
The round was led by led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount. Other premier life sciences investors also participated, including Fidelity Management & Research Company, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Sanofi Ventures, Woodline Partners LP, Venrock Healthcare Capital Partners, RTW Investments and Alexandria Venture Investments.
The company intends to use the funds to advance its programs.
Founded by Mark C. McKenna and led by several former executives of Prometheus Biosciences (acquired in 2023 by Merck for $10.8 billion), Mirador is a precision medicine company focused on immunology and inflammation. The company’s Mirador360TM precision development engine leverages advances in human genetics and data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases.
FinSMEs
25/03/2024